Gilles Salles, MD, PhD, is a professor of hematology and medicine at the University of Lyon, and head of the Department of Hematology at the Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, in Pierre-Bénite, France.
Professor Salles obtained his doctoral degree in differentiation, genetics, and immunology, as well as his medical degree, from Université Claude Bernard Lyon-1. He completed further training in oncology and also served as a researcher at the Dana-Farber Cancer Institute of Harvard Medical School in Boston, Massachusetts, USA.
For more than 25 years, Professor Salles has been especially interested in the clinical and biological study of lymphoma. The primary focus of his work is on the description and validation of prognostic factors and clinical trials in indolent lymphomas. He has also been involved in the investigation and development of new therapeutic agents, such as targeted therapies, new monoclonal antibodies and other immunotherapies in the field.
His research team, “Clinical and Experimental Models of Lymphomagenesis,” at the Cancer Research Center of Lyon, is examining several aspects of lymphoma biology: T- and B-cell lymhoma models, signaling, genomic biology of indolent lymphomas, and prognostic factors.
Previously, Professor Salles chaired the Scientific Committee of the Adult Lymphoma Study Group and is now the chair of the Lymphoma Study Association, a European cooperative group. He is also a member of several international societies, including the American Society of Hematology.
Professor Salles is the author of more than 300 publications, including articles in international peer-reviewed journals such as The New England Journal of Medicine, Blood, Journal of Clinical Oncology, The Lancet, Haematologica, Lancet Oncology, and Leukemia and Lymphoma.